2012 Scrip 100: Drug delivery innovations bring compliance and cost savings
This article was originally published in Scrip
Executive Summary
Patient noncompliance places a huge cost on healthcare budgets on a global level. Peter Thornton looks at new drug delivery options that could solve this costly problem, as healthcare providers come under pressure to control ever escalating costs.
You may also be interested in...
Sanofi mulls Lyxumia lixisenatide market positioning with ADA data
Data unveiled at the American Diabetes Association (ADA) 71st scientific sessions suggests that while Lyxumia (lixisenatide), from Sanofi, dosed once daily had met its endpoint of non-inferiority to Byetta (exenatide) in the treatment of Type 2 diabetes, the real battle will be to take on Victoza, (liraglutide), the once daily injectable GLP-1 analogue from Novo Nordisk. Moreover, it is likely that Sanofi will not pursue obesity as a target indication for lixisenatide.